Your browser doesn't support javascript.
loading
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors.
Diamond, Jennifer R; Pitts, Todd M; Ungermannova, Dana; Nasveschuk, Christopher G; Zhang, Gan; Phillips, Andrew J; Bagby, Stacey M; Pafford, Jessica; Yacob, Betelehem W; Newton, Timothy P; Tentler, John J; Gittleman, Brian; Hartman, Sarah J; DeMattei, John A; Winkler, James D; Wendt, Michael K; Schiemann, William P; Eckhardt, S Gail; Liu, Xuedong; Piscopio, Anthony D.
Afiliación
  • Diamond JR; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Pitts TM; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Ungermannova D; University of Colorado Boulder, Boulder, Colorado.
  • Nasveschuk CG; University of Colorado Boulder, Boulder, Colorado.
  • Zhang G; University of Colorado Boulder, Boulder, Colorado.
  • Phillips AJ; University of Colorado Boulder, Boulder, Colorado.
  • Bagby SM; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Pafford J; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Yacob BW; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Newton TP; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Tentler JJ; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Gittleman B; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Hartman SJ; University of Colorado Cancer Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • DeMattei JA; OnKure, Inc., Boulder, Colorado.
  • Winkler JD; OnKure, Inc., Boulder, Colorado.
  • Wendt MK; Purdue University Center for Cancer Research, Lafayette, Indiana.
  • Schiemann WP; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio.
  • Eckhardt SG; Department of Oncology, Dell Medical School, University of Texas at Austin, Austin, Texas.
  • Liu X; University of Colorado Boulder, Boulder, Colorado.
  • Piscopio AD; OnKure, Inc., Boulder, Colorado.
Mol Cancer Ther ; 21(3): 397-406, 2022 03 01.
Article en En | MEDLINE | ID: mdl-34965958
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Neoplasias Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Inhibidores de Histona Desacetilasas / Neoplasias Límite: Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2022 Tipo del documento: Article Pais de publicación: Estados Unidos